top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
New Alpha DaRT Research Collaboration on Immune Stimulation in the Treatment of Breast Cancer
JERUSALEM, Jan 20, 2022 – Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha...
Jan 20, 2022
Results of First US Clinical Trial of Alpha DaRT™
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response...
Jan 10, 2022
Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
JERUSALEM, Dec. 31, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
Jan 3, 2022
Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
JERUSALEM, Nov. 3, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
Nov 4, 2021
Completion of Enrollment in 1st US Clinical Trial & Achievement of 1st Primary Objective
JERUSALEM, Oct. 25, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
Oct 26, 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to...
Oct 12, 2021
Alpha Tau & Healthcare Capital Corp. to Combine and Create A $1-Billion Publicly Traded Company
Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Treatment of Solid...
Jul 11, 2021
First Alpha DaRT Patient Treated in the US as Part of Pilot Multicenter Skin Cancer Trial
Jerusalem, Israel, July 6, 2021 - Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRTTM,...
Jul 8, 2021
Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™
JERUSALEM, June 8, 2021 /PRNewswire/ -- Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT,TM...
Jun 13, 2021
Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
Tel Aviv, Israel, June 4, 2020 - Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased...
Jun 4, 2020
bottom of page